International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Comparison of the prognostic value of the neutrophil to lymphocyte ratio with other prognostic indices in the prognosis of patients diagnosed with multiple myeloma
The high neutrophil to lymphocyte ratio (NLR) is a poor prognostic factor for patients with multiple myeloma (MM); however, it has yet to be widely recognized in clinical practice. The present study was conducted to determine the value of NLR in the prognosis of patients with MM, compared with other prognostic indices. In total, 109 patients with newly diagnosed MM who were undergoing chemotherapy were recruited in the present retrospective cohort study. The prognostic factors subjected to analysis for survival time were determined at the time of pre‑treatment. The results of the univariate and multivariate analyses revealed that only a high bone marrow plasma cell percentage (≥40%), a low platelet count (<150x109/l), a high NLR (≥2.1) and a high calcium level (≥2.75 mmol/l) were poor prognostic factors for both overall survival (OS) and progression‑free survival (PFS). In the OS analysis, the hazard ratios (HRs) of a high bone marrow plasma cell percentage (≥40%), low platelet count (<150x109/l), high NLR (≥2.1) and high calcium level (≥2.75 mmol/l) were 1.900, 1.839, 2.605 and 2.665, with P=0.039, 0.049, 0.003 and 0.003, respectively. The absolute value of standardized coefficient β values for OS were 0.065, 0.039, 0.141 and 0.212, respectively. In the PFS analysis, the HRs of high bone marrow plasma cell percentage (≥40%), low platelet count (<150x109/l), high NLR (≥2.1) and high calcium level (≥2.75 mmol/l) were 1.721, 1.876, 2.326 and 2.354, with P=0.044, 0.026, 0.002 and 0.004, respectively. Moreover, values for the absolute value of standardized coefficient β (for PFS) were 0.149, 0.099, 0.186 and 0.207. Collectively, the results of the present study revealed that a high NLR (≥2.1) may exhibit a higher potential for determining a poor prognosis than a high bone marrow plasma cell percentage (≥40%) and a low platelet count (<150x109/l); however, it may be less useful than high calcium levels (≥2.75 mmol/l).